[Code of Federal Regulations]
[Title 32, Volume 1]
[Revised as of July 1, 2003]
From the U.S. Government Printing Office via GPO Access
[CITE: 32CFR58.3]

[Page 293]
 
                       TITLE 32--NATIONAL DEFENSE
 
              CHAPTER I--OFFICE OF THE SECRETARY OF DEFENSE
 
PART 58--HUMAN IMMUNODEFICIENCY VIRUS (HIV-1)--Table of Contents
 
Sec. 58.3  Definitions.

    (a) Human Immunodeficiency Virus-1 (HIV-1). The virus most commonly 
associated with the Acquired Immune Deficiency Syndrome (AIDS) in the 
United States.
    (b) HIV-1 and/or AIDS Education Program. Any combination of 
information, education, and behavior-change strategies designed to 
facilitate behavioral alteration that will improve or protect health. 
Included are those activities intended to support or influence 
individuals in managing their own health through lifestyle decisions and 
self-care. Operationally, such programs include community, worksite, and 
clinical aspects using appropriate public health education 
methodologies.
    (c) Serologic Evidence of HIV-1 Infection. A reactive result given 
by a Food and Drug Administration (FDA)-approved enzyme-linked 
immunosorbent assay (ELISA) serologic test that is confirmed by a 
reactive and diagnostic immunoelectrophoresis test (Western blot (WB)) 
test on two separate samples.
    (d) Host Nation. A foreign nation to which DoD U.S. civilian 
employees are assigned to perform their official duties.
    (e) DoD Civilian Employees. Current and prospective DoD U.S. 
civilian employees, including appropriated and nonappropriated fund 
personnel. This does not include members of the family of DoD civilian 
employees, employees of, or applicants for, positions with contractors 
performing work for the Department of Defense, or their families.
    (f) Epidemiological Assessment. The process by which personal and 
confidential information on the possible modes of transmission of HIV-1 
are obtained from an HIV-1 infected person. This information is used to 
determine if previous, present, or future contacts of the infected 
individual are at risk for infection with HIV-1 and to prevent further 
transmission of HIV-1.